Clinical trials: Sunitinib
Renal Carcinoma Metastatic, Kidney Neoplasms
Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma
Physician mainly use RECIST progression-free survival (PFS) and NCI CTCAE safety as a guide to evaluate treatment efficiency. In contrast Health Related Quality of Life (HRQOL) assessment is often restricted to clinical trial.
- Conditions
- Renal Carcinoma Metastatic, Kidney Neoplasms, Renal Cancer
- Trial name
- QUANARIE (NCT03062410)
- Testing
- Electronic PRO in daily clinical practice
- Where
- 8 sites in France
- Volunteers
- 56 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Papillary Renal Cell Carcinoma
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally…
- Trial name
- PRCC (NCT07024680)
- Testing
- Observational, None intervention
- Where
- China
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
This phase II trial is studying how well sunitinib works in treating patients with recurrent and/or metastatic head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00387335
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Prostate Cancer
Phase II Sunitinib Prog Met AIPC
The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.
- Trial name
- NCT00599313
- Testing
- Sunitinib
- Where
- 45 sites in United States
- Volunteers
- 36 people
- Sponsor
- US Oncology Research
Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia
Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysethesia (PPE), occurs in a 25%-50% of patients treated with several commonly used anti-cancer drugs including capecitabine and sunitinib.
- Trial name
- JADE (NCT01219023)
- Testing
- sildenafil citrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Renal Cell Carcinoma
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.
- Trial name
- NCT00975806
- Testing
- Lenalidomide, Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Advanced Gastrointestinal Stromal Tumors
Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
The treatment of advanced GIST patients is based on imatinib followed with sunitinib in case of resistance/intolerance. However, the median progression-free survival (PFS) on sunitinib is frequently short, and after failure with…
- Trial name
- CYCLIGIST (NCT01907607)
- Testing
- PD 0332991
- Where
- 9 sites in France
- Volunteers
- 29 people
- Sponsor
- Institut Bergonié
Gastrointestinal Stromal Tumors
Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
The study evaluated the safety and efficacy of nilotinib versus current treatment in adults with gastrointestinal stromal tumors (GIST) who have either progressed or who were intolerant to the first and second line treatments.
- Trial name
- ENEST (NCT00471328)
- Testing
- Nilotinib, Best Supportive Care (BSC) +/- imatinib or sunitinib
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Cognitive/Functional Effects, Metastatic Cancer
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00910039
- Testing
- sunitinib malate, cognitive assessment
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Kidney Cancers
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib
Metastatic renal cell carcinomas (mRCC) are highly angiogenic tumors because of mutation of the pVHL gene leading to over-expression of VEGF.
- Trial name
- SUNITRES (NCT03097601)
- Testing
- ELR+CXCL cytokines levels are of sunitinib response
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Antoine Lacassagne
Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors
Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
The primary objectives are: Dose escalation: 1. To determine the MTD and DLT(s) of TH-302 when used in combination with sunitinib. Dose expansion: 1.
- Conditions
- Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors, Pancreatic Neuroendocrine Tumors
- Trial name
- TH-CR-410 (NCT01381822)
- Testing
- TH-302
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Threshold Pharmaceuticals
Breast Neoplasms
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
- Trial name
- NCT00373256
- Testing
- Sunitinib, paclitaxel, bevacizumab
- Where
- 250 sites in United States, Germany and 2 more
- Volunteers
- 488 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
Functional Imaging in the Assessment of mRCC Response to Sunitinib
The aim of this study is to assess whether functional magnetic resonance imaging (MRI) techniques are able to detect which patients with metastatic renal cell carcinoma will derive benefit from treatment with anti-angiogenic…
- Trial name
- NCT01977586
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- United Kingdom
- Sponsor
- Imperial College Healthcare NHS Trust
Carcinoma, Renal Cell
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease progression of patients with metastatic Renal Cell…
- Trial name
- NCT00522249
- Testing
- Pegylated Alfa Interferon, sunitinib, erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Methodist Hospital Research Institute
Prostate Cancer
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
The goal of this clinical research study is to learn if the addition of sunitinib malate (SU011248) to hormone based castration is an effective treatment for shrinking or controlling the tumor before having the prostate removed.
- Trial name
- NCT00329043
- Testing
- LHRH Agonist, Sunitinib Malate, Radical Prostatectomy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Metastatic Renal Cell Carcinoma
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
Stereotactic radiotherapy (SRT) is a newer type of focused radiation therapy that precisely and accurately delivers high dose radiation to a tumour, while sparing much of the nearby normal organs.
- Trial name
- NCT02019576
- Testing
- Stereotactic radiotherapy
- Where
- 12 sites in Canada
- Volunteers
- 38 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Renal Cell Carcinoma, Kidney Neoplasm
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
The purpose of the open-label INDIGO-study is to examine whether a first line individualized treatment strategy based on DNA and RNA analyses from the patient's tumor is feasible.
- Conditions
- Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms
- Trial name
- INDIGO (NCT04644432)
- Testing
- Medication (A specification is listed under each arm), Patient reported outcomes measurement
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Herlev and Gentofte Hospital
Breast Neoplasms
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
The purpose of this study is to compare progression free survival for SU011248 [sutent (sunitinib malate)] versus standard of care therapy in patients with previously treated, advanced, triple receptor negative (ER, PR, HER2)…
- Trial name
- NCT00246571
- Testing
- SU011248, Chemotherapy
- Where
- 113 sites in United States, Bulgaria and 10 more
- Volunteers
- 217 people
- Sponsor
- Pfizer
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00482911
- Testing
- cyclophosphamide, lenalidomide, sunitinib malate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hypertension
Angiogenesis Inhibitors and Hypertension: Clinical Aspects
The aim of the study is to find simple clinical and laboratory parameters to predict the development of hypertension and to elucidate the mechanism of hypertension during treatment with the tyrosine kinase inhibitor Sunitinib.
- Trial name
- NCT00511511
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center